Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.94
+0.180010.23%
Post-market: 1.92-0.0192-0.99%19:52 EDT
Volume:717.96K
Turnover:1.41M
Market Cap:2.88M
PE:-0.01
High:2.10
Open:1.82
Low:1.81
Close:1.76
52wk High:524.00
52wk Low:1.43
Shares:1.49M
Float Shares:1.48M
Volume Ratio:13.39
T/O Rate:48.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-114.61%
ROA:-51.35%
PB:0.25
PE(LYR):-0.01

Loading ...

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

TIPRANKS
·
May 26

Clearmind says Johns Hopkins IRB clears next stages of CMND-100 Phase I/II trial

Reuters
·
May 26

Clearmind Medicine Announces Johns Hopkins Irb Approval to Advance Cmnd-100 Phase I/Ii Clinical Trial to the Next Parts

THOMSON REUTERS
·
May 26

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
May 21

Clearmind Medicine Inc trading halted, news pending

TIPRANKS
·
May 21

Top Premarket Decliners

MT Newswires Live
·
May 19

Clearmind agrees to convert $600,000 notes into common shares at $0.3 each

Reuters
·
May 19

Clearmind Medicine announces 1-for-10 reverse share split

TIPRANKS
·
May 19

Clearmind Medicine to execute 1-for-10 reverse stock split May 21

Reuters
·
May 19

BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split

Reuters
·
May 19

Clearmind Medicine Announces 1-for-10 Reverse Share Split

THOMSON REUTERS
·
May 19

Clearmind Medicine to sell USD 600,000 convertible notes at 90% of face value

Reuters
·
May 19

Clearmind Medicine signs new research agreement with Yissum Research Development

TIPRANKS
·
May 18

Clearmind signs preclinical study of MEAI with tirzepatide in obese mice

Reuters
·
May 18

Clearmind Medicine Signs Agreement to Examine Meai in Combination and Sequencing With Tirzepatide Against Blockbuster Glp-1 Medications

THOMSON REUTERS
·
May 18

Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.

THOMSON REUTERS
·
May 15

Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4

Reuters
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder

THOMSON REUTERS
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire
·
May 12

Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data

Reuters
·
May 11